However, an increase in tumor-associated CXCR2+ neutrophils compensated for the beneficial effects of CCR2+ macrophage-targeted therapy; therefore, targeting both myeloid cell types appears to be critical to improve response to chemotherapy.64 Here, CXCR2 is linked to neoplasm.